These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Evaluation of New Tests and Interventions for Prostate Cancer Management: A Systematic Review. Olleik G; Kassouf W; Aprikian A; Hu J; Vanhuyse M; Cury F; Peacock S; Bonnevier E; Palenius E; Dragomir A J Natl Compr Canc Netw; 2018 Nov; 16(11):1340-1351. PubMed ID: 30442734 [No Abstract] [Full Text] [Related]
3. Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2]proprostate-specific antigen-based prostate health index for detection of prostate cancer. Stephan C; Jung K; Semjonow A; Schulze-Forster K; Cammann H; Hu X; Meyer HA; Bögemann M; Miller K; Friedersdorff F Clin Chem; 2013 Jan; 59(1):280-8. PubMed ID: 23213079 [TBL] [Abstract][Full Text] [Related]
4. Novel biomarkers and genomic tests in prostate cancer: a critical analysis. Falzarano SM; Ferro M; Bollito E; Klein EA; Carrieri G; Magi-Galluzzi C Minerva Urol Nefrol; 2015 Sep; 67(3):211-31. PubMed ID: 26054411 [TBL] [Abstract][Full Text] [Related]
5. Genomic Markers in Prostate Cancer Decision Making. Cucchiara V; Cooperberg MR; Dall'Era M; Lin DW; Montorsi F; Schalken JA; Evans CP Eur Urol; 2018 Apr; 73(4):572-582. PubMed ID: 29129398 [TBL] [Abstract][Full Text] [Related]
6. Optimizing prostate cancer screening; prospective randomized controlled study of the role of PSA and PCA3 testing in a sequential manner in an opportunistic screening program. Rubio-Briones J; Casanova J; Dumont R; Rubio L; Fernandez-Serra A; Casanova-Salas I; Domínguez-Escrig J; Ramírez-Backhaus M; Collado A; Gómez-Ferrer A; Iborra I; Monrós JL; Ricós JV; Solsona E; Salas D; Martínez F; Lopez-Guerrero JA Actas Urol Esp; 2014 May; 38(4):217-23. PubMed ID: 24169211 [TBL] [Abstract][Full Text] [Related]
7. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment. Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884 [TBL] [Abstract][Full Text] [Related]
8. Reducing unnecessary biopsies while detecting clinically significant prostate cancer including cribriform growth with the ERSPC Rotterdam risk calculator and 4Kscore. Verbeek JFM; Bangma CH; Kweldam CF; van der Kwast TH; Kümmerlin IP; van Leenders GJLH; Roobol MJ Urol Oncol; 2019 Feb; 37(2):138-144. PubMed ID: 30528698 [TBL] [Abstract][Full Text] [Related]
9. Improving the Specificity of PSA Screening with Serum and Urine Markers. Kearns JT; Lin DW Curr Urol Rep; 2018 Aug; 19(10):80. PubMed ID: 30105509 [TBL] [Abstract][Full Text] [Related]
10. Blood-based and urinary prostate cancer biomarkers: a review and comparison of novel biomarkers for detection and treatment decisions. Hendriks RJ; van Oort IM; Schalken JA Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):12-19. PubMed ID: 27922627 [TBL] [Abstract][Full Text] [Related]
11. Determination of the percentage of free prostate-specific antigen helps to avoid unnecessary biopsies in men with normal rectal examinations and total prostate-specific antigen of 4-10 ng/ml. Martínez-Piñeiro L; Tabernero A; Contreras T; Madero R; Lozano D; López-Tello J; Alonso-Dorrego JM; Picazo ML; González Gancedo P; Martínez-Piñeiro JA; de La Peña JJ Eur Urol; 2000 Mar; 37(3):289-96. PubMed ID: 10720854 [TBL] [Abstract][Full Text] [Related]
12. Combination of Prostate Cancer Antigen 3 and Prostate-Specific Antigen Improves Diagnostic Accuracy in Men at Risk of Prostate Cancer. Cao L; Lee CH; Ning J; Handy BC; Wagar EA; Meng QH Arch Pathol Lab Med; 2018 Sep; 142(9):1106-1112. PubMed ID: 29547000 [TBL] [Abstract][Full Text] [Related]
13. Novel Biomarkers for Prostate Cancer Detection and Prognosis. Filella X; Foj L Adv Exp Med Biol; 2018; 1095():15-39. PubMed ID: 30229547 [TBL] [Abstract][Full Text] [Related]
14. Prostate Cancer Detection and Prognosis: From Prostate Specific Antigen (PSA) to Exosomal Biomarkers. Filella X; Foj L Int J Mol Sci; 2016 Oct; 17(11):. PubMed ID: 27792187 [TBL] [Abstract][Full Text] [Related]
15. Prostate health index and prostate cancer gene 3 score but not percent-free Prostate Specific Antigen have a predictive role in differentiating histological prostatitis from PCa and other nonneoplastic lesions (BPH and HG-PIN) at repeat biopsy. De Luca S; Passera R; Fiori C; Bollito E; Cappia S; Mario Scarpa R; Sottile A; Franco Randone D; Porpiglia F Urol Oncol; 2015 Oct; 33(10):424.e17-23. PubMed ID: 26162485 [TBL] [Abstract][Full Text] [Related]
16. Prostate-specific antigen: does the current evidence support its use in prostate cancer screening? Duffy MJ Ann Clin Biochem; 2011 Jul; 48(Pt 4):310-6. PubMed ID: 21525152 [TBL] [Abstract][Full Text] [Related]
17. [New challenges and earlier approved methods in the laboratory diagnosis of prostate cancer]. Kovács GL Magy Onkol; 2014 Dec; 58(4):301-9. PubMed ID: 25517448 [TBL] [Abstract][Full Text] [Related]
19. Twenty-year Risk of Prostate Cancer Death by Midlife Prostate-specific Antigen and a Panel of Four Kallikrein Markers in a Large Population-based Cohort of Healthy Men. Sjoberg DD; Vickers AJ; Assel M; Dahlin A; Poon BY; Ulmert D; Lilja H Eur Urol; 2018 Jun; 73(6):941-948. PubMed ID: 29519548 [TBL] [Abstract][Full Text] [Related]
20. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy. Auprich M; Augustin H; Budäus L; Kluth L; Mannweiler S; Shariat SF; Fisch M; Graefen M; Pummer K; Chun FK BJU Int; 2012 Jun; 109(11):1627-35. PubMed ID: 21939492 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]